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ABSTRACT
Aims We assessed to what degree smokers who fail to quit on the target quit date (TQD) or lapse following TQD
eventually achieve success with continued treatment. Design A secondary analysis of pooled data of successful
quitterstreatedwithvarenicline(306of 696),bupropion(199of 671)andplacebo(121of 685)fromtwoidentically-
designed clinical trials of varenicline versus bupropion sustained-release and placebo. Setting Multiple research
centers in the US. Participants Adult smokers (n = 2052) randomized to 12 weeks drug treatment plus 40 weeks
follow-up. Measurement The primary end-point for the trials was continuous abstinence for weeks 9–12. TQD was
day 8. Two patterns of successful quitting were identiﬁed. Immediate quitters (IQs) were continuously abstinent for
weeks 2–12. Delayed quitters (DQs) smoked during 1 or more weeks for weeks 2–8. Findings Cumulative continuous
abstinence (IQs + DQs) increased for all treatments during weeks 3–8. Overall IQs and DQs for varenicline were (24%;
20%) versus bupropion (18.0%, P = 0.007; 11.6%, P < 0.001) or placebo (10.2%, P < 0.001; 7.5%, P < 0.001).
However, DQs as a proportion of successful quitters was similar for all treatments (varenicline 45%; bupropion 39%;
placebo 42%) and accounted for approximately one-third of those remaining continuously abstinent for weeks 9–52.
No gender differences were observed by quit pattern. Post-treatment relapse was similar across groups. Conclusions
Our data support continuing cessation treatments without interruption for smokers motivated to remain in the
quitting process despite lack of success early in the treatment.
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INTRODUCTION
Cigarette smoking remains a critical public health
problem, resulting in unnecessary illness and deaths
world-wide [1]. While effective smoking cessation treat-
ments,includingcounseling,socialsupportandpharma-
cotherapies [1], are widely available, quitting success
rates can vary signiﬁcantly [2]. Even among those who
receive evidence-based treatments, adherence to recom-
mendations is often poor, with negative implications for
treatment outcomes [3,4], suggesting the importance
of longer-term adherence support for those patients
attempting actively to quit smoking.
Adverse events, fear of becoming dependent upon
medicationandcosthaveallbeenassociatedwithprema-
ture discontinuation of pharmacological treatments
[5,6]. An area receiving more recent attention has to do
with the role played by different deﬁnitions of quitting
success or abstinence in treatment outcomes [2,7,8].
Deﬁnitions of treatment failure linked to the target quit
day (TQD) [9,10] may contribute to interruption of an
active quitting process [3,7], when smokers believe they
havealreadyfailedduetoinabilitytoachieveinitialabsti-
nence or maintain continuous abstinence after the
planned TQD. Additionally, drug labeling that cautions
patients about risks of smoking while using nicotine
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insurance guidelines such as those of the National Insti-
tute for Health and Clinical Excellence (NICE) in the
United Kingdom, that assess quit success at 4 weeks after
the TQD [13], may have the unintended effect of prema-
turely shortening the duration of treatment for those not
abstinent at 4 weeks. This is despite evidence supporting
enhanced efﬁcacy with better adherence to recom-
mended duration of therapy [1,6,14].
No uniform standard has been established for when
‘smoking abstinence’ should be assessed [2]. The deﬁni-
tions of abstinence can vary considerably [2], including
24hours[8,10,15,16],4weeksfollowingaTQD[17]and
the last 4 weeks of treatment [18], as well as other inter-
vals [2,7].
The deﬁnition of abstinence employed can result in
decisions to change, interrupt or discontinue treatments,
as has been suggested for those who fail to quit on, or
shortly after, a TQD [9,10]. In an effort to guide more
uniformity and ﬂexibility when treating smokers, the
Society of Research on Nicotine andTobacco (SRNT) rec-
ommended including a 2-week ‘grace period following
the TQD when assessing successful abstinence’ [18].
However, successful quitting in clinical practice and
much of the literature remains focused upon abstinence
end-points [7,8], while much remains unknown about
quitting and smoking behaviors [19]. Quitting patterns
and processes during a quit attempt is an under-
investigated but emerging area of research [7,8,20]. Pre-
vious research has not established the degree to which
motivated smokers who fail to achieve immediate absti-
nenceontherecommendedTQD,orwhoexperienceearly
lapses,wouldeventuallyachievecontinuousabstinenceif
treatment were not interrupted or discontinued. Second-
ary analyses of data from drug efﬁcacy trials can expand
our knowledge of quitting processes beyond the TQD.
Although these trials are focused upon abstinence end-
points, often the last 4 weeks of treatment [8,18], absti-
nence data are collected beginning with the TQD. All
participants, regardless of abstinence status, are encour-
aged to take the study drug, to continue in their attempts
to achieve or maintain abstinence and to remain actively
engaged for the entire treatment period [21,22]. The
result is a rich database for analyses of quitting patterns
throughout the treatment period and across various
treatment types.
To investigate successful quitting patterns among all
those achieving continuous abstinence for weeks 9–12, a
post hoc analysis was conducted on pooled data from two
identical varenicline versus bupropion sustained-release
(SR) and placebo randomized controlled trials (RCTs).
Ourpurposewastoexaminethecontributionof twosub-
groups of successful quitters who achieved continuous
abstinence for at least the last 4 weeks of treatment. One
group quit on theTQD and remained continuously absti-
nent throughout the 12-week treatment period. The
other group had periods of smoking prior to attaining
continuous abstinence for at least the last 4 weeks. In
addition to examining overall patterns of successful quit-
ting, we tested two primary hypotheses with respect to
differentialmedicationeffects.First,becausevarenicline’s
partial agonist and antagonist activity at a4b2 receptors
has been reported to be linked to reduction in pleasure
and reward from smoking [21,22], we hypothesized that
quitting patterns for participants in the varenicline arm
may be more dynamic across the 12 weeks of treatment
compared with participants in the bupropion SR or
placebo (counseling alone) arms. That is, we expected
that smokers unable to achieve abstinence on theTQD or
who experienced early lapses would be more likely to
recover if they were in the varenicline arm.Therefore, we
predicted that the varenicline arm would have a higher
proportion of delayed quitters than the other two arms.
Secondly, we hypothesized that the experience of reduced
rewards when smoking while taking varenicline may
blunt motivation to return to smoking and provide some
protection from relapse post-drug treatment.
METHODS
Setting and participants
The overall design and methodology of these trials have
been described previously in full in published primary
manuscripts [21,22].
Brieﬂy,bothstudieswereidenticallydesignedrandom-
ized, double-blind, placebo-controlled trials conducted
between June 2003 and April 2005. Participants were
generally healthy adult smokers. Those with any history
of bupropion or varenicline exposure were excluded to
reduce risk of re-treatment bias [23].
Interventions
Participantsineachstudywererandomizedatbaselineto
receive varenicline, bupropion or placebo for 12 weeks.
All participants were provided with a self-help booklet on
smoking cessation (Clearing the Air: How to Quit Smoking
[24]) at baseline.TheTQD followed the ﬁrst week of drug
treatment and was day 8 (week 1 visit). These were
placebo-controlled trials with respect to drug assign-
ments, but all arms, including placebo, included brief
cessation counseling (up to 10 minutes) [25] at baseline
andclinicvisitsforweeks1to13,24,36,44and52.Brief
(5-minute) telephone counseling calls were scheduled for
day 3 after theTQD and at weeks 16, 20, 28, 32, 40 and
48 during the non-treatment follow-up. Smoking status
was assessed at clinic visits during active treatment
(weeks 1–12) and the non-drug treatment follow-up
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monoxide (CO) was measured during clinic visits to
conﬁrm smoking status.
Outcomes
The primary end-point of both trials was continuous
abstinence (not even a puff) for weeks 9–12, and con-
ﬁrmedbyCOlevels10partspermillion(p.p.m.)atclinic
visits. A secondary end-point was continuous abstinence
for weeks 9–52 conﬁrmed at in-clinic visits.
Pooled analyses of overall efﬁcacy data have been
reportedpreviously[26].Thisposthocanalysisof quitting
patterns of pooled data for successful quitters is the ﬁrst
tobeconducted.Successfulquittersweredeﬁnedasthose
who met the criteria of continuous abstinence for the
primary end-points (weeks 9–12). Successful quitters
were classiﬁed further as either ‘immediate quitters’ (IQs)
or‘delayedquitters’(DQs).IQsachievedinitialabstinence
immediately on the day 8 TQD and remained continu-
ouslyabstinentforweeks2–12.ThetermDQswasusedto
categorize all those who ﬁrst quit later than theirTQD, as
well as those who quit on schedule, but smoked in a sub-
sequent week(s), and were then able to achieve continu-
ous abstinence for weeks 9–12. Thus, DQs includes all
those who were ‘delayed’ in successfully achieving con-
tinuous abstinence for the primary end-point: weeks
9–12.
Analysis
All analyses were conducted on pooled data from the two
studies. Analyses of continuous abstinence for weeks
9–12 and weeks 9–52 were conducted for the two quit-
ting patterns. Continuous abstinence rates (IQs + DQs)
were analyzed weekly for weeks 2–12 to assess cumula-
tive rates of continuous abstinence. The rates of relapse
for IQs and DQs were assessed during the non-treatment
follow-up at weeks 13, 24, 36, 44 and 52 and compared
across all three treatment arms (varenicline, bupropion
SR and placebo) based on the sample of all successful
end-of-treatment quitters and by quitting pattern (IQs
and DQs). In addition, for the continuous abstinence for
weeks9–52,theinteractionbetweentreatmentarmsand
quitting pattern was investigated.
Fortheprimaryandsecondaryend-points,analysesto
assess treatment effects were performed using logistic
regression models with treatment group and study as the
main effects. Hypotheses were tested using two-tailed
likelihood-ratio c2 tests with a signiﬁcance level of 0.05.
Odds ratios (OR) and 95% conﬁdence intervals (CI) for
continuous abstinence rates were calculated.
For the continuous abstinence for weeks 9–52, the
interaction effect between treatment arms and quitting
pattern was assessed using a logistic regression model,
including the main effects of treatment, study and quit-
ting pattern and the treatment ¥ quitting pattern inter-
action.
To assess comparability across treatment groups,
demographics and baseline characteristics were summa-
rized by treatment group for the pooled all-randomized
sample and for each quitting pattern subsample.
All analyses were performed using SAS version 8 in a
UNIX platform.
RESULTS
Participant disposition
Of the 2052 randomized participants from the two trials
(Fig. 1), those meeting the criteria for successful quitters
were 306 of 696 for varenicline, 199 of 671 for bupro-
pion and 121 of 685 for placebo.
Baseline characteristics of the all-randomized sample
and the subsamples of successful quitters (IQs and DQs)
for each of the treatment groups are shown in Table 1.
The mean baseline Fagerström Test for Nicotine Depen-
dence (FTND) [27] scores were lower in the IQs and DQs
than in their corresponding all-randomized treatment
group sample, except for the bupropion DQ group. No
gender differences by quitting pattern were observed.
Demographic characteristics and smoking histories of
the overall sample were generally comparable across
treatment groups (Table 1).
Patterns of successful quitting during the drug
treatment period: immediate and delayed
Successful quitting (continuous abstinence for weeks
9–12) included IQs (continuously abstinent weeks 2–12)
and DQs (smoked at 1 or more weeks for weeks 2–8).The
cumulative rates of continuous abstinence increased
with each week of treatment up to weeks 9–12, regard-
less of type of treatment (Fig. 2).
Overall, a signiﬁcantly greater percentage of the total
randomized varenicline participants compared with
bupropion SR participants were IQs (24.0% versus
18.0%, P = 0.007) and DQs (20.0% versus 11.6%,
P < 0.001). This was also true of varenicline versus
placebo (IQs, 24.0% versus 10.2%, P < 0.001; DQs,
20.0% versus 7.5%, P < 0.001). There were also signiﬁ-
cantly greater percentages of IQs and DQs in the bupro-
pionSRgroupthantheplacebogroup(IQs,18.0%versus
10.2%, P < 0.001; DQs, 11.6% versus 7.5%, P = 0.009).
Analysiswith‘successfulquittersonly’asthedenomi-
nator revealed that DQs as a proportion of successful
quitters was similar across the three treatment arms.
Forty-ﬁve per cent of successful varenicline quitters were
DQs versus 39% for bupropion SR (P = 0.161) and 42%
2004 David Gonzales et al.
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portions were statistically signiﬁcant (Fig. 3).
Abstinence status for each individual DQ participant
for the weeks following the TQD (weeks 2–12) are pre-
sented in Fig. 4.
Post-treatment abstinence
Resultsfromthelogisticregressionanalysis(basedonthe
total number of participants who were continuously
abstinent from weeks 9 to 12) showed a statistically sig-
niﬁcant(P = 0.001)effectof quittingpatternoncontinu-
ous abstinence to week 52, with DQs less likely to remain
abstinent. However, treatment effect was not statisti-
cally signiﬁcant (P = 0.782 varenicline versus placebo;
P = 0.983 varenicline versus buproprion SR; P = 0.784
buproprion versus placebo), nor was the interaction
betweentreatmentarmandquittingpattern(P = 0.239).
DQsmadeupapproximatelyone-thirdof theparticipants
whoremainedcontinuouslyabstinentfromweeks9to52
regardless of treatment group.
Rates of relapse (decline in continuous abstinence)
Analysisusingthetotalnumberof participantswhowere
continuously abstinent from weeks 9 to 12 in each treat-
ment group in the denominator shows that the relative
rate of decline in continuous abstinence following the
end-of-treatmenttoweek52issimilarforeachtreatment
group (Fig. 5). There was no signiﬁcant difference
between the relapse rates at week 24 and week 52 across
treatment groups. There was a signiﬁcant effect of quit
patternsubgroups(IQsversusDQs)onweek24andweek
52continuousabstinence(P  0.001,Fig. 5).Therewas
no treatment ¥ subgroup interaction at either week 24
(P = 0.159) or week 52 (P = 0.239).
DISCUSSION
In this secondary analysis of pooled data from two iden-
tical varenicline versus bupropion and placebo trials, two
successful quitting patterns were identiﬁed among
smokers who achieved continuous abstinence for the last
Figure 1 Participant disposition
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(IQs) quit on theTQD (day 8) and remained continuously
abstinent for weeks 2–12. Delayed quitters (DQs)
achieved initial abstinence some time after the TQD or
may have lapsed following abstinence at week 2 and
recoveredbyweek9of thetrial.ComparedtoIQstheDQs
were ‘delayed’ in achieving continuous abstinence to the
end-of-treatment.
Although varenicline produced a greater total
number of abstinent participants for weeks 9–12, our
ﬁrst hypothesis that quitting might be more dynamic for
smokers treated with varenicline was not supported.Two
unexpected ﬁndings from our analyses were that IQ and
DQ patterns were similar regardless of treatment group,
and that the majority of DQs remained continuously
abstinent to the end-of-treatment, following their ﬁrst
reported week of no smoking. Most did not lapse (Fig. 4).
Our data expand upon ﬁndings from recent studies of
quitting processes and patterns and suggest that IQ and
DQ may be natural patterns in treatment-seeking
smokers, regardless of therapy. In one report self-quitters
who intended to quit abruptly (IQ) were often unable to
do so on the TQD, but continued to work towards initial
abstinence [7]. NRT-treated smokers who continued
treatment despite lapsing also showed a pattern of
increasing abstinence over time [8]. Both studies
described quitting smoking as a dynamic process that
could extend beyond the TQD and suggested that inter-
vening following a lapse could reduce risk of complete
relapse. No special intervention was provided for our DQs
to help with either achieving initial continuous absti-
nence or with lapse recovery. For many smokers who
could become successful DQs, adhering to the planned
treatment duration may be a sufﬁcient intervention to
improve abstinence outcomes. Collectively, ours and the
other emerging data have begun to demonstrate that
quittingsmokingisamorecomplexanddynamicprocess
than previously understood, and one that can extend
beyond the TQD and persist for several weeks [7,8,20].
Previously published reports from these trials indi-
cated that varenicline-treated participants had signiﬁ-
cantly greater reductions in some of the reinforcing
Figure 2 Cumulative contributions of immediate quitters (IQs) and delayed quitters (DQs) to continuous abstinence rates,week X to week
12. Varenicline versus bupropion SR IQs (24.0%, 18.0%; P=0.007); DQs (20.0%, 11.6%; P<0.001). Varenicline versus placebo IQs (24.0%,
10.2%;P<0.001);DQs (20.0%,7.5%;P<0.001).Bupropion SR versus placebo IQs (18.0%,10.2%;P<0.001) and DQs (11.6%,7.5%;P=0.009)
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logical reward and pleasure [21,22]. These observations
and others that reported enjoyment of smoking as a
barrier to quit attempts [19] led to our second hypothesis
that varenicline may provide some protection from post-
treatment relapse in successful quitters. Because partici-
pantswerenotencouragedtoabstainfromsmokingprior
to theTQD (day 8 of treatment), all had some experience
with smoking combined with the effects of varenicline.
We thought that motivation to return to smoking after
the end-of-treatment might be blunted due to recently
experienced blunted effects when smoking while taking
varenicline. This hypothesis was not supported. Vareni-
clinedidnotprovideadditionalprotectionagainstrelapse
post-treatment. Instead, we found that post-treatment
relapse rates were nearly identical for successful quitters
in all treatment groups and by quitting pattern. Even
thoughDQsinallgroupsmadeupasubstantialportionof
those who remained continuously abstinent to week 52,
they experienced more post-treatment relapse than IQs.
These higher relapse rates suggest that a smoker’s ability
to abstain from smoking on theTQD and to remain absti-
nent during treatment is also linked to the maintenance
of long-term abstinence. At ﬁrst glance, this ﬁnding
appears consistent with earlier research showing that
any smoking after theTQD predicts poorer outcomes [9].
However, as we and others have shown, successful quit-
ting processes are more complex than can be assessed
adequately shortly after the TQD or based on lapses
[7,8,20].
Recent analyses from a varenicline relapse prevention
trialsuggestedthatextendingtreatmentbeyondthestan-
dard 12 weeks would be especially helpful for quitters
who achieved initial abstinence after the TQD [20]. Pre-
vious data published from that trial [28] and a bupropion
relapse prevention trial [29] provided the basis for allow-
ing up to 24 weeks of treatment being included in the
package inserts [17,30]. Nicotine dependence is a
chronic condition and post-treatment relapse is common
[1]. Identiﬁcation of which successful quitters might be
more likely to beneﬁt from an extended period of treat-
ment to prevent relapse could help guide the clinician’s
treatment decisions. A recent analysis of data from these
trials suggests that those continuously abstinent from
TQD were less likely to relapse than those abstinent only
for weeks 9–12 [31]. We speculate that DQs may be more
likely to beneﬁt from additional weeks of treatment, but
this has not been tested directly. Counseling post-12
weeks may also aid in preventing relapse.
This is the ﬁrst analysis that we are aware of that
investigates the quitting patterns of smokers treated with
varenicline, bupropion or counseling alone (placebo)
Figure 3 Continuous abstinence rates,weeks 9–12,by quit pattern,immediate or delayed.Differences between treatment groups were not
signiﬁcant
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successful end-of-treatment quitters. There are several
important features of the studies from which the data
were analyzed. These were two large randomized
placebo-controlled trials that included a head-to-head
comparison of two smoking cessation drugs and placebo.
Because the same level of brief cessation counseling was
providedinallarms,theplaceboarmcouldbeconsidered
a surrogate for ‘counseling alone’. Overall, treatment
completion rates were consistent with prior trials of
bupropion [32,33].
There are limitations to our analyses that may limit
interpretation of the results for a broader population of
smokers.This was a post hoc analysis of quitting patterns
for successful end-of-treatment quitters. Unsuccessful
quitting patterns were not assessed. We felt that analyz-
ingpatternsof successfulquitterscouldhavemoreimme-
diate practical relevance to clinical practice and there
have been other ‘quitters only’ analyses reported in the
literature [34]. Investigation of patterns for unsuccessful
quitters would be an important next step to expanding
our understanding of quitting patterns overall.
In addition, participants were generally healthy, moti-
vated to quit smoking and received up to 10 minutes of
face-to-face cessation counseling every week during
treatment and at clinic visits during post-drug follow-up.
Counseling treatments available outside clinical trials
that provide fewer or briefer sessions may result in poorer
abstinence outcomes, and proportions of DQs may vary.
Lastly, treatment with NRT was not part of the study
design, and quitting patterns for 12 weeks of NRT treat-
ment may vary from the two patterns identiﬁed in our
analyses.
Our data and those from other recent studies offer a
more optimistic picture about the potential effects of
pharmacological and behavioral treatment following
lapses[8]andfailurestoquitontheTQD[7].Byadjusting
the deﬁnition of treatment success so that failure-to-quit
on the TQD [9,10], or lapsing [35], are not regarded as
treatment failure and persisting with treatment over the
entire recommended period, it seems likely that more
smokers could be successful even without additional
relapse prevention interventions. However, there are
some challenges to adopting this newer approach. Revi-
Figure 4 Weekly abstinence status of delayed quitters (DQs) following the day 8 TQD weeks 2–12. Most DQs remained continuously
abstinent from the point of the ﬁrst week of abstinence and did not lapse. DQs who lapsed generally re-established abstinence in the week
following the lapse
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treatment more directly may be needed. Currently, labels
for NRT in many countries warn patients not to smoke
while using NRT and to consider postponing their efforts
to quit by the fourth week of treatment, if abstinence has
not been achieved [11,12]. The label for bupropion SR
may discourage continued treatment and delayed quit-
ting by indicating that smoking after a quit date signiﬁ-
cantly reduces chance of success [30]. The label for
varenicline that encourages patients to continue treat-
ment and continue attempting to achieve abstinence
despite lapses [17] may be a good model to support
delayed quitting. Clinicians and tobacco treatment spe-
cialists would need to adjust messaging to patients and
revise treatment protocols to support continuation of
treatment. Lastly, health insurance beneﬁt coverage for
smoking cessation treatment and government guidelines
regardingtreatmentsuccesscanplayarole.Forexample,
the NICE guidelines assess cessation success at 4 weeks
following the TQD [13]. Our data suggest that assessing
success at a later point might result in capturing addi-
tional quitters.
In summary, an important question for clinicians to
consider in smoking cessation treatment is whether or
not to modify, interrupt or continue a speciﬁc treatment
for motivated smokers who fail to achieve or to maintain
continuous abstinence following a planned TQD. Previ-
ous studies have not reported sufﬁcient evidence to guide
these decisions. Our data show that among quitters who
completed any of the treatments, a substantial propor-
tion failed to achieve abstinence on the planned TQD or
had lapses prior to quitting successfully. Had treatment
been interrupted or discontinued for these ‘delayed quit-
ters’, opportunities for achieving continuous abstinence
could have been lost for up to 45% of successful quitters.
These data support recommending continuing cessation
treatments without interruption for smokers motivated
to remain in the quitting process despite lack of success
early in treatment.
Clinical trial registration
Clinicaltrials.gov Identiﬁer: NCT00141206 and
NCT00143364
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